Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T35063
|
||||
Former ID |
TTDNC00413
|
||||
Target Name |
KIR
|
||||
Gene Name |
GEM
|
||||
Synonyms |
GTPbinding mitogeninduced Tcell protein; GTPbinding protein GEM; RASlike protein KIR; GEM
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Acute myeloid leukemia [ICD9: 205; ICD10: C92.0] | ||||
Function |
Could be a regulatory protein, possibly participating in receptor-mediated signal transduction at the plasma membrane. Has guanine nucleotide-binding activity but undetectable intrinsic GTPase activity.
|
||||
BioChemical Class |
Small GTPase superfamily
|
||||
UniProt ID | |||||
Sequence |
MTLNNVTMRQGTVGMQPQQQRWSIPADGRHLMVQKEPHQYSHRNRHSATPEDHCRRSWSS
DSTDSVISSESGNTYYRVVLIGEQGVGKSTLANIFAGVHDSMDSDCEVLGEDTYERTLMV DGESATIILLDMWENKGENEWLHDHCMQVGDAYLIVYSITDRASFEKASELRIQLRRARQ TEDIPIILVGNKSDLVRCREVSVSEGRACAVVFDCKFIETSAAVQHNVKELFEGIVRQVR LRRDSKEKNERRLAYQKRKESMPRKARRFWGKIVAKNNKNMAFKLKSKSCHDLSVL |
||||
Drugs and Mode of Action | |||||
Drug(s) | Lirilumab | Drug Info | Phase 2 | Acute myeloid leukemia | [1] |
Modulator | Lirilumab | Drug Info | [2] | ||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
NetPath Pathway | FSH Signaling Pathway | ||||
IL4 Signaling Pathway | |||||
References | |||||
REF 1 | ClinicalTrials.gov (NCT02481297) Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients. | ||||
REF 2 | Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model. J Immunother Cancer. 2013; 1(Suppl 1): P40. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.